卢冰

       卢冰，区域高发疾病方向肿瘤机制与干预研究课题学术带头人。国贴获得者，中华医学会放射肿瘤治疗学分会副主任委员、中国临床肿瘤学会放射肿瘤专家委员会副主任委员、中华医学会肿瘤学分会委员、中华医学会医疗鉴定专家库成员、《中华放射肿瘤学杂志》编委、贵州省医学会肿瘤学分会主任委员。承担国家自然科学基金、国家多中心临床研究项目以及各类省级重点项目10余项。获国家科技进步二等奖1项，贵州省科技进步二等奖1项，发表科研论文80余篇。培养博硕士生40余名。

研究方向

肺癌及胸部肿瘤的临床实践和临床研究

代表性论文

1. Q Li,N Liang,W Ouyang,S Su,Y Geng,Y Hu,H Li,B Lu. Advanced non-small-cell lung cancer with malignant pleural effusion may require primary tumor radiotherapy in addition to drug therapy. International Journal of Radiation Oncology*Biology*Physics.2020;108(3):130.

2. Qing-Song Li, Na Liang, Wei-Wei Ouyang, Sheng-Fa Su, Zhu Ma, Yi-Chao Geng, Wen-Gang Yang, Yin-Xiang Hu, Hui-Qin Li, Bing Lu*. Simultaneous integrated boost of intensity-modulated radiation therapy to Stage II-III non-small cell lung cancer with metastatic lymph nodes. Cancer Medicine. 2020;9:8364-8372.

3. ShengFa Su, LingFeng Liu, YiChao Geng, WeiWei OuYang, Zhu Ma, QingSong Li, ChaoFen Zhao, Mei Li, Yu Wang, DaXian Luo, WenGang Yang, ZhiXu He, Bing Lu*. Pemetrexed plus cisplatin versus docetaxel plus cisplatin for stage IV lung adenocarcinoma based on propensity score matching. Anti-Cancer Drugs. 2019; 30: 295-301.

4. Sheng-Fa Su#, Mei Li#, Yi-Chao Geng#, Wen-Gang Yang, Zhu Ma, Qing-Song Li, Yin-Xiang Hu, Wei-Wei Ou Yang, Ling-Feng Liu, Bing Lu*. Randomized phase II study of pemetrexed-cisplatin or docetaxel-cisplatin plus thoracic intensity-modulated radiation therapy in patients with stage IV lung adenocarcinoma. Am J Cancer Res. 2019; 9(6): 1235-1245.

5. Sheng-Fa Su#, Mei Li#, Yi-Chao Geng#, Wen-Gang Yang, Zhu Ma, Qing-Song Li, Yin-Xiang Hu,Wei-Wei Ou Yang, Ling-Feng Liu, Bing Lu*. Randomized phase II study of pemetrexed-cisplatin or docetaxel-cisplatin plus thoracic intensity-modulated radiation therapy in patients with stage IV lung adenocarcinoma. Am J Cancer Res. 2019;9(6):1235-1245.